Bluebird Bio stock rises 62%, FDA committee supports treatments

Shares of Bluebird Bio Inc. rally more than 60% after news that a U.S. FDA committee supports two of the company's gene therapies.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.